A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia Meeting Abstract
| Authors: | Goldberg, A. D.; Ohanian, M.; Koller, P. B.; Cherry, M.; Altman, J. K.; Tomlinson, B.; Chandhok, N. S.; Haney, D. N.; Hu, J.; Sinha, R. K.; Rice, W. G.; Bejar, R. |
| Abstract Title: | A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6220 |
| End Page: | 6221 |
| Language: | English |
| ACCESSION: | WOS:000893223206103 |
| DOI: | 10.1182/blood-2022-167759 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
